Payment overview · 2025
General Payments
$50,627.25
203 reported records · 17 companies
Healthcare provider profile · identity verified
Eric J Campbell, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · EDMOND, OK · NPI 1861482887
Verified facts
What the public records show
CMS Open Payments records show Eric J Campbell, PA-C received $50,627.25 in general payments during 2025 across 203 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Rinvoq, Saphnelo, Simponi Aria, Tremfya, Xeljanz.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rinvoq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SAPHNELO as an associated drug or biological on 16430 records involving 3390 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Saphnelo by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Benlysta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI ARIA as an associated drug or biological on 28612 records involving 8458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Simponi Aria by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Tremfya by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xeljanz by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $12,538.07 | 24.8% | 39 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $11,981.50 | 23.7% | 23 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $7,890.75 | 15.6% | 19 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $6,480.30 | 12.8% | 16 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $5,786.07 | 11.4% | 27 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $3,674.39 | 7.3% | 38 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $1,333.72 | 2.6% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $335.88 | 0.7% | 21 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $146.24 | 0.3% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $135.06 | 0.3% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $122.19 | 0.2% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.60 | 0.1% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.48 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.77 | 0.1% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $27.49 | 0.1% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $26.79 | 0.1% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $25.95 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,544.00 | 22 |
| Consulting Fee | $8,630.00 | 3 |
| Travel and Lodging | $7,762.90 | 16 |
| Food and Beverage | $5,690.35 | 162 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $12,444.13 | 38 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $11,981.50 | 23 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $11,808.54 | 14 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $7,890.75 | 19 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $6,430.62 | 14 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $5,562.99 | 25 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $3,037.96 | 8 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $383.29 | 17 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $248.80 | 16 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $173.95 | 5 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $87.08 | 5 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $73.75 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $60.60 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $60.22 | 6 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $32.48 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| Gel-One Cross-linked Hyaluronate Normalized: gel one cross linked hyaluronate |
Device | Zimmer Biomet Holdings, Inc. | $27.49 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| ILARIS Normalized: ilaris |
Drug | Novartis Pharmaceuticals Corporation | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| REMICADE Normalized: remicade |
Biological | Janssen Biotech, Inc. | $12.69 | 1 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $8.75 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $8.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SAPHNELO saphnelo |
2025 | Saphnelo | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SIMPONI ARIA simponi aria |
2025 | Simponi Aria | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XELJANZ xeljanz |
2025 | Xeljanz | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SAPHNELO open payments reported associated product |
CMS Open Payments — General Payments 16430 supporting records · 3390 recipient NPIs · example record 1206131348 |
Saphnelo · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI ARIA open payments reported associated product |
CMS Open Payments — General Payments 28612 supporting records · 8458 recipient NPIs · example record 1174257377 |
Simponi Aria · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XELJANZ open payments reported associated product |
CMS Open Payments — General Payments 32588 supporting records · 8614 recipient NPIs · example record 1228794176 |
Xeljanz · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 335 | 103 |
| Prednisone | Prednisone | 225 | 92 |
| Methotrexate | Methotrexate Sodium | 113 | 33 |
| Leflunomide | Leflunomide | 109 | 28 |
| Meloxicam | Meloxicam | 107 | 33 |
| Gabapentin | Gabapentin | 98 | 31 |
| Tramadol Hcl | Tramadol Hcl | 85 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 21 |
| Sulfasalazine Dr | Sulfasalazine | 74 | 30 |
| Celecoxib | Celecoxib | 69 | 27 |
| Sulfasalazine | Sulfasalazine | 68 | 13 |
| Nabumetone | Nabumetone | 67 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Enbrel Sureclick | Etanercept | 47 | suppressed |
| Ondansetron Odt | Ondansetron | 47 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 14 |
| Rinvoq | Upadacitinib | 45 | suppressed |
| Allopurinol | Allopurinol | 41 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 12 |
| Cevimeline Hcl | Cevimeline Hcl | 39 | 11 |
| Azathioprine | Azathioprine | 38 | 13 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Armodafinil | Armodafinil | 30 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Omeprazole | Omeprazole | 28 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 18 |
| Saphnelo | Anifrolumab-Fnia | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 21 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | suppressed |
| Tremfya | Guselkumab | 16 | suppressed |
| Xeljanz | Tofacitinib Citrate | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Teriparatide | Teriparatide | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Benlysta | Belimumab | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 13 | suppressed |
| Simponi Aria | Golimumab | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 11 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Orencia Clickject | Abatacept | 11 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $50,627.25 · 203 records | AstraZeneca Pharmaceuticals LP | ACTHAR, BENLYSTA, Bimzelx, COSENTYX, ENBREL, EVENITY, Gel-One Cross-linked Hyaluronate, ILARIS, KRYSTEXXA, ORENCIA, OTEZLA, PROLIA, PURIFIED CORTROPHIN GEL, REMICADE, RINVOQ, SAPHNELO, SIMPONI ARIA, SKYRIZI, STRENSIQ, TAVNEOS, TREMFYA, UPLIZNA, XELJANZ | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error